Drugs / GSK3352589
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03154086 | May 2017 → Mar 2018 | irritable bowel syndrome | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3352589 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03154086 ↗ |
| Action | Inhibit | “GSK3352589 is an RET kinase inhibitor” PMID 33606922 ↗ Feb 2021 |
| Route | Oral | “escalating single and repeat oral doses of GSK3352589” NCT03154086 ↗ |
| Target | RET | “GSK3352589 is an RET kinase inhibitor” PMID 33606922 ↗ Feb 2021 |